Filtros de búsqueda

Lista de obras de Marcello Tiseo

"Pseudocavitation" in thymic carcinoma during treatment with sunitinib.

artículo científico publicado en 2013

'Turban-like' skull metastasis from pulmonary adenocarcinoma

artículo científico publicado en 2016

2PD Monitoring of secondary drug resistance mutations in circulating tumor DNA of patients with advanced ALK positive NSCLC.

artículo científico publicado en 2016

A Phase 1 Study of mTORC1/2 Inhibitor BI 860585 as a Single Agent or with Exemestane or Paclitaxel in Patients with Advanced Solid Tumors

artículo científico publicado en 2020

A metanalysis on cabozantinib and bone metastases: true story or commercial gimmick?

scientific article published on 01 March 2020

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable

artículo científico publicado en 2019

A phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in pretreated patients with small-cell lung cancer

artículo científico publicado en 2013

ALK and ROS1 rearrangements tested by fluorescence in situ hybridization in cytological smears from advanced non-small cell lung cancer patients.

artículo científico publicado en 2015

ALK-positive adenocarcinoma of the lung expressing neuroendocrine markers and presenting as a "pituitary adenoma".

artículo científico publicado en 2017

Accuracy of Fine Needle Aspiration Cytology in the Pathological Typing of Non-small Cell Lung Cancer

article

Activity of Pemetrexed on brain metastases from Non-Small Cell Lung Cancer.

artículo científico publicado en 2009

Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors.

artículo científico publicado en 2014

Adding PD-1/PD-L1 Inhibitors to Chemotherapy for the First-Line Treatment of Extensive Stage Small Cell Lung Cancer (SCLC): A Meta-Analysis of Randomized Trials

scientific article published on 16 September 2020

Adjuvant chemotherapy for non-small cell lung cancer: ready for clinical practice?

artículo científico publicado en 2005

Advantages of multidetector-row CT with multiplanar reformation in guiding percutaneous lung biopsies

artículo científico publicado en 2008

An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): data report from Italy

artículo científico publicado en 2008

Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs).

artículo científico publicado en 2016

Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer.

artículo científico publicado en 2011

Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-r

scientific article published on 04 February 2020

Anti-PD-1-related cryoglobulinemia during treatment with nivolumab in NSCLC patient.

artículo científico publicado en 2017

Asymptomatic pulmonary embolism in lung cancer: prevalence and analysis of clinical and radiological characteristics in 141 outpatients

article

BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients: Results from a multicenter Italian observational study.

artículo científico publicado en 2016

BOLERO-3 results: pharmacological activity or pharmacokinetic effect?

artículo científico publicado en 2014

BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall.

artículo científico publicado en 2018

Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.

artículo científico publicado en 2017

Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer

scientific article published on 25 September 2018

Buccal mucosa cells as in vivo model to evaluate gefitinib activity in patients with advanced non small cell lung cancer

artículo científico publicado en 2007

CEA serum level as early predictive marker of outcome during EGFR-TKI therapy in advanced NSCLC patients.

artículo científico publicado en 2015

COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study

artículo científico publicado en 2020

CT-guided biopsy of pulmonary nodules: is pulmonary hemorrhage a complication or an advantage?

artículo científico publicado en 2014

Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study

artículo científico publicado en 2020

Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancer

artículo científico publicado en 2015

Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis

artículo científico publicado en 2007

Classification of different patterns of pulmonary adenocarcinomas.

artículo científico

Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study

scientific article published on 22 February 2019

Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab

artículo científico publicado en 2018

Clinical implications and future perspectives in testing non-small cell lung cancer (NSCLC) for anaplastic lymphoma kinase (ALK) gene rearrangements.

artículo científico publicado en 2015

Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50

artículo científico publicado en 2020

Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation.

artículo científico publicado en 2016

Combination of target agents: challenges and opportunities.

artículo científico publicado en 2007

Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells.

artículo científico publicado en 2017

Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines

artículo científico publicado en 2012

Comparison between epidermal growth factor receptor (EGFR) gene expression in primary non-small cell lung cancer (NSCLC) and in fine-needle aspirates from distant metastatic sites

artículo científico publicado en 2008

Concomitant EGFR and KRAS mutations in ALK-rearranged lung cancer.

artículo científico publicado en 2015

Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC.

artículo científico publicado en 2018

Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA.

artículo científico publicado en 2016

Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC).

artículo científico publicado en 2013

Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-treated advanced non-small-cell lung cancer patients.

artículo científico publicado en 2011

Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients

scientific article published on 21 February 2019

Crizotinib Resensitization by Compound Mutation.

artículo científico publicado en 2016

Current status of second-line treatment and novel therapies for small cell lung cancer.

artículo científico publicado en 2007

Curved Needles in CT-Guided Fine Needle Biopsies of Abdominal and Retroperitoneal Small Lesions

artículo científico

Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer

artículo científico publicado en 2006

Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment.

artículo científico publicado en 2017

Detection of ROS1 rearrangement in non-small cell lung cancer: current and future perspectives

artículo científico publicado en 2017

Different clinical effects upon separate inhibition of coexisting EGFR and PI3KCA mutations in a lung adenocarcinoma patient.

artículo científico publicado en 2014

Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH) Syndrome and Carcinoid Tumors With/Without NECH: A Clinicopathologic, Radiologic, and Immunomolecular Comparison Study.

artículo científico publicado en 2018

Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia syndrome

artículo científico publicado en 2016

Does Immunohistochemistry Represent a Robust Alternative Technique in Determining Drugable Predictive Gene Alterations in Non-Small Cell Lung Cancer?

artículo científico

Dramatic response to crizotinib in ROS1 fluorescent in situ hybridization- and immunohistochemistry-positive lung adenocarcinoma: a case series.

artículo científico publicado en 2014

EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations.

artículo científico publicado en 2010

EGFR mutation-specific antibodies in pulmonary adenocarcinoma: a comparison with DNA direct sequencing.

artículo científico publicado en 2012

EPMA-World Congress 2015

artículo científico publicado en 2016

ERCC1 and small cell lung cancer

artículo científico publicado en 2010

ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin

artículo científico publicado en 2013

Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines

artículo científico publicado en 2015

Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index

artículo científico publicado en 2020

Efficacy and safety of influenza vaccination during chemotherapy treatment

scientific article published on 01 November 2010

Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial

artículo científico publicado en 2017

Efficacy and safety of long-term tolvaptan treatment in a patient with SCLC and SIADH.

artículo científico publicado en 2015

Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer.

artículo científico publicado en 2016

Efficacy of the CDK4/6 Dual Inhibitor Abemaciclib in EGFR-Mutated NSCLC Cell Lines with Different Resistance Mechanisms to Osimertinib

artículo científico publicado en 2020

Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC).

artículo científico publicado en 2010

Endometrial metastasis of lung adenocarcinoma: a case report

artículo científico publicado en 2011

Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN

artículo científico publicado en 2017

Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism

artículo científico publicado en 2017

Enteral administration of TKIs: report of a response to ceritinib in an ALK-positive NSCLC patient and literature review

artículo científico publicado en 2018

Epidermal growth factor receptor and Kras gene expression: reliability of mutational analysis on cytological samples.

artículo científico publicado en 2012

Epidermal growth factor receptor inhibitors: a new prospective in the treatment of lung cancer.

artículo científico publicado en 2004

Epidermal growth factor receptor intron-1 polymorphism predicts gefitinib outcome in advanced non-small cell lung cancer

artículo científico publicado en 2008

Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC).

artículo científico publicado en 2003

Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer

artículo científico

Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study

artículo científico publicado en 2020

Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines

artículo científico publicado en 2009

Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines

Expert opinions of the first italian consensus conference on the management of malignant pleural mesothelioma

scientific article published on February 2011

Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials.

artículo científico publicado en 2018

Expression levels of some antioxidant and epidermal growth factor receptor genes in patients with early-stage non-small cell lung cancer.

artículo científico publicado en 2010

Extra-pleuric coaxial system for CT-guided percutaneous fine-needle aspiration biopsy (FNAB) of small (≤20 mm) lung nodules: a novel technique using multiplanar reconstruction (MPR) images.

artículo científico publicado en 2016

FGFR as potential target in the treatment of squamous non small cell lung cancer

artículo científico

Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study

artículo científico publicado en 2018

First-line chemotherapy treatment of advanced non-small-cell lung cancer: does cisplatin versus carboplatin make a difference?

artículo científico publicado en 2014

First-line treatment in advanced non-small-cell lung cancer: the emerging role of the histologic subtype

artículo científico publicado en 2009

Fishing for ALK with immunohistochemistry may predict response to crizotinib.

artículo científico publicado en 2013

Functional characterization of gefitinib uptake in non-small cell lung cancer cell lines.

artículo científico publicado en 2010

Gefitinib and afatinib treatment in an advanced non-small cell lung cancer (NSCLC) patient undergoing hemodialysis

Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification

artículo científico publicado en 2013

Gene mutations in small-cell lung cancer (SCLC): results of a panel of 6 genes in a cohort of Italian patients

artículo científico publicado en 2014

Grading the neuroendocrine tumors of the lung: an evidence-based proposal.

artículo científico publicado en 2013

Granulocyte growth factors in the treatment of non-small cell lung cancer (NSCLC).

artículo científico publicado en 2006

How to develop novel treatments for EGFR-mutant lung cancer.

artículo científico publicado en 2015

INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study

Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study

artículo científico publicado en 2020

In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines.

artículo científico publicado en 2005

Induction chemotherapy with carboplatin-paclitaxel followed by standard radiotherapy with concurrent daily low-dose cisplatin plus weekly paclitaxel for inoperable non-small-cell lung cancer

scientific article published on 01 February 2005

Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations

artículo científico publicado en 2015

Is cytology reliable for epidermal growth factor receptor gene evaluation in non-small cell lung cancer?

artículo científico publicado en 2010

Is immunohistochemistry always required to diagnose lung cancer?

artículo científico publicado en 2013

Is the door open to further investigation with antiangiogenesis in SCLC?

artículo científico publicado en 2018

Isolation and Characterization of Circulating Tumor Cells in Squamous Cell Carcinoma of the Lung Using a Non-EpCAM-Based Capture Method.

artículo científico publicado en 2015

Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA)

article

Italian cohort of nivolumab Expanded Access Programme (EAP): Preliminary data from a real-world population

artículo científico publicado en 2016

Italian multicenter phase III randomized study of cisplatin-etoposide with or without bevacizumab as first-line treatment in extensive stage small cell lung cancer: treatment rationale and protocol design of the GOIRC-AIFA FARM6PMFJM trial

artículo científico publicado en 2014

Italian multicenter survey to evaluate the opinion of patients and their reference clinicians on the "tolerance" to targeted therapies already available for non-small cell lung cancer treatment in daily clinical practice

artículo científico publicado en 2014

Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial.

artículo científico publicado en 2017

K-RAS mutations indicating primary resistance to crizotinib in ALK-rearranged adenocarcinomas of the lung: Report of two cases and review of the literature

artículo científico publicado en 2016

L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR-Mutated NSCLC.

artículo científico publicado en 2016

L718Q mutant EGFR escapes covalent inhibition by stabilizing a non-reactive conformation of the lung cancer drug osimertinib.

artículo científico publicado en 2018

Liquid Biopsy Testing Can Improve Selection of Advanced Non-Small-Cell Lung Cancer Patients to Rechallenge with Gefitinib

scientific article published on 25 September 2019

Localized Malignant Pleural Mesothelioma: Report of Two Cases

artículo científico publicado en 2009

Low PD-1 Expression in Cytotoxic CD8+ Tumor-Infiltrating Lymphocytes Confers an Immune-Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value

artículo científico publicado en 2017

Lung Toxicity in Non-Small-Cell Lung Cancer Patients Exposed to ALK Inhibitors: Report of a Peculiar Case and Systematic Review of the Literature.

artículo científico publicado en 2017

MET DNA Alterations in NSCLC-Letter.

artículo científico publicado en 2016

MET and ALK as targets for the treatment of NSCLC.

artículo científico publicado en 2014

MET and Small-Cell Lung Cancer

artículo científico publicado en 2014

Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across Europe

artículo científico publicado en 2012

Maintenance therapy in NSCLC: why? To whom? Which agent? ⬇️

artículo científico publicado en 2011

Management of locally advanced non-small cell lung cancer in the modern era: A national Italian survey on diagnosis, treatment and multidisciplinary approach

artículo científico publicado en 2019

Mechanisms of Resistance to Target Therapies in Non-small Cell Lung Cancer.

artículo científico publicado en 2017

Metabolic complete response with vinflunine as second-line therapy in a kidney-transplanted patient with advanced urothelial carcinoma: a case report.

artículo científico publicado en 2016

Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines.

artículo científico publicado en 2011

Methodological issues in the choice among different drugs approved for the same therapeutic indication: a position paper by the Italian Association of Medical Oncology (AIOM).

artículo científico publicado en 2016

MicroRNA Expression in Malignant Pleural Mesothelioma and Asbestosis: A Pilot Study.

artículo científico publicado en 2017

Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective study.

artículo científico publicado en 2017

Moving Immune Checkpoint Blockade in Thoracic Tumors beyond NSCLC.

artículo científico publicado en 2016

Multi-target inhibitors in non-small cell lung cancer (NSCLC).

artículo científico publicado en 2006

Mutational Profile of Malignant Pleural Mesothelioma (MPM) in the Phase II RAMES Study

scientific article published on 13 October 2020

NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial

scientific article published on 09 May 2018

NSE level in combined neuroendocrine and adenocarcinoma EGFR mutated lung cancer resistant to EGFR-TKI.

artículo científico publicado en 2013

Nivolumab-Induced Guillain-Barré Syndrome Coupled With Remarkable Disease Response in a Case of Heavily Pretreated Lung Adenocarcinoma

scientific article published on 21 November 2019

No room for statins in the quest for survival benefits in small cell lung cancer.

artículo científico publicado en 2018

Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition

artículo científico publicado en 2017

Osteoblastic progression during EGFR tyrosine kinase inhibitor therapy in mutated non-small cell lung cancer: a potential blunder.

artículo científico publicado en 2015

Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study

artículo científico publicado en 2017

Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis

artículo científico publicado en 2015

Overcoming T790M-driven acquired resistance to EGFR-TKIs in NSCLC with afatinib: a case report.

artículo científico publicado en 2014

Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The PRACTICE study

scientific article published on 13 December 2019

Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment.

artículo científico publicado en 2017

Pazopanib in Renal Cell Carcinoma Dialysis Patients: A Mini-Review and a Case Report.

artículo científico publicado en 2016

Pemetrexed Versus Pemetrexed and Carboplatin As Second-Line Chemotherapy in Advanced Non–Small-Cell Lung Cancer: Results of the GOIRC 02-2006 Randomized Phase II Study and Pooled Analysis With the NVALT7 Trial

article

Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin.

artículo científico publicado en 2012

Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy.

artículo científico publicado en 2017

Plasma and EBC microRNAs as early biomarkers of non-small-cell lung cancer

artículo científico publicado en 2013

Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: does cisplatin versus carboplatin make a difference?

artículo científico publicado en 2005

Predictive and prognostic significance of neuron-specific enolase (NSE) in non-small cell lung cancer.

artículo científico publicado en 2008

Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib.

artículo científico publicado en 2013

Predictive factors of diagnostic accuracy of CT-guided transthoracic fine-needle aspiration for solid noncalcified, subsolid and mixed pulmonary nodules.

artículo científico publicado en 2013

Predictive role of erythrocyte macrocytosis during treatment with pemetrexed in advanced non-small cell lung cancer patients

artículo científico publicado en 2015

Predictors of clinical response of non-small cell cancer to gefitinib

artículo científico publicado en 2004

Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers.

artículo científico publicado en 2009

Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy

artículo científico publicado en 2017

Prognostic role of hyponatremia in 564 small cell lung cancer patients treated with topotecan

scientific article published on 02 August 2014

Prognostic value of 18F-FDG standard uptake value by integrated PET/CT in the staging of malignant pleural mesothelioma.

artículo científico publicado en 2012

Radiotherapy of non-small-cell lung cancer in the era of EGFR gene mutations and EGF receptor tyrosine kinase inhibitors

artículo científico

Randomized phase III PITCAP trial and meta-analysis of induction chemotherapy followed by thoracic irradiation with or without concurrent taxane-based chemotherapy in locally advanced NSCLC.

artículo científico publicado en 2016

Refractory pleural small cell carcinoma in never smoker. A case report.

artículo científico publicado en 2008

Reliability of EGFR and KRAS mutation analysis on fine-needle aspiration washing in non-small cell lung cancer.

artículo científico publicado en 2013

Risk of recurrent venous thromboembolism and major hemorrhage in cancer-associated incidental pulmonary embolism among treated and untreated patients: a pooled analysis of 926 patients.

artículo científico publicado en 2015

Second-line Treatment of Small Cell Lung Cancer: Is Platinum Sensitivity a Relevant Prognostic Factor?

artículo científico publicado en 2015

Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.

artículo científico publicado en 2011

Second-line chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC).

artículo científico publicado en 2004

Semiautomatic Analysis on Computed Tomography in Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Reproducibility and Prognostic Significance of Unidimensional and 3-dimensional Measurements.

artículo científico publicado en 2015

Short hydration regimen and nephrotoxicity of intermediate to high-dose cisplatin-based chemotherapy for outpatient treatment in lung cancer and mesothelioma

artículo científico publicado en 2007

Tackling ALK in non-small cell lung cancer: the role of novel inhibitors

artículo científico publicado en 2016

Targeting the MET gene for the treatment of non-small-cell lung cancer

artículo científico publicado en 2013

The Prognostic Role of High Blood Cholesterol in Advanced Cancer Patients Treated With Immune Checkpoint Inhibitors

artículo científico publicado en 2020

The Role of c-Met as a Biomarker and Player in Innate and Acquired Resistance in Non-Small-Cell Lung Cancer: Two New Mutations Warrant Further Studies

scientific article published on 04 December 2019

The Third Italian Consensus Conference for Malignant Pleural Mesothelioma: State of the art and recommendations

artículo científico publicado en 2016

Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC

Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance.

artículo científico publicado en 2016

Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines.

artículo científico publicado en 2017

Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance

artículo científico publicado en 2014

Treatment in EGFR-mutated non-small cell lung cancer: how to block the receptor and overcome resistance mechanisms.

artículo científico publicado en 2017

Treatment of Unfit Patients With Advanced Non-Small-Cell Lung Cancer: Definition Criteria According an Expert Panel.

artículo científico

Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB-IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST).

artículo científico publicado en 2012

Typhlitis during second-line chemotherapy with pemetrexed in non-small cell lung cancer (NSCLC): A case report

artículo científico publicado en 2009

Validation of standard definition of sensitive versus refractory relapsed small cell lung cancer: a pooled analysis of topotecan second-line trials.

artículo científico publicado en 2014

Widespread Nivolumab-induced Enteropathy in a Long Responder Non–Small-cell Lung Cancer Patient

artículo científico publicado en 2018

YKL-40 and mesothelin in the blood of patients with malignant mesothelioma, lung cancer and asbestosis

artículo científico publicado en 2013

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda